Royalty Pharma Forecasted Growth
Future criteria checks 4/6
Royalty Pharma is forecasted to grow earnings and revenue by 82.7% and 7.3% per annum respectively. EPS is expected to grow by 82.6%. Return on equity is forecast to be 29.3% in 3 years.
Earnings growth rate
EPS growth rate
|Pharmaceuticals earnings growth||18.5%|
|Revenue growth rate||7.3%|
|Future return on equity||29.3%|
|Last updated||06 Sep 2023|
Recent future growth updates
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year'sMay 12
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20Apr 20
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20Jan 16
Royalty Pharma to co-fund development of schizophrenia drug with MerckOct 12
Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant GrowthAug 18
Royalty Pharma declares $0.19 dividendJul 15
Royalty Pharma: Unique Diversification, Bear Market PerformerMay 26
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)Apr 25
Royalty Pharma Offers A Unique Long-Term Investment OpportunityMar 01
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19Jan 25
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19Jan 11
Royalty Pharma: A Pharma-Like Company Without The Same RisksDec 27
Royalty Pharma Provides Unique Diversity To A Biopharma PortfolioOct 27
Royalty Pharma (RPRX) MorphoSys Transaction CallJun 11
Royalty Pharma: A Potentially Long-Term Dividend InvestmentMay 04
Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% DividendMar 08
Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?Feb 01
Royalty Pharma raises dividend by 13% to $0.17 per shareJan 08
Earnings and Revenue Growth Forecasts
|Date||Revenue||Earnings||Free Cash Flow||Cash from Op||Avg. No. Analysts|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPRX's forecast earnings growth (82.7% per year) is above the savings rate (2.2%).
Earnings vs Market: RPRX's earnings (82.7% per year) are forecast to grow faster than the US market (15.4% per year).
High Growth Earnings: RPRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RPRX's revenue (7.3% per year) is forecast to grow slower than the US market (7.7% per year).
High Growth Revenue: RPRX's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (29.3%)